187 related articles for article (PubMed ID: 37335322)
21. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
22. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Moore L; Bartels T; Persky DO; Abraham I; Kumar A; McBride A
Support Care Cancer; 2021 Aug; 29(8):4867-4874. PubMed ID: 33547525
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
Younes A; Burke JM; Diefenbach C; Ferrari S; Khan C; Sharman JP; Tani M; Ujjani C; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Gilbertson M
Blood Adv; 2022 Oct; 6(20):5659-5667. PubMed ID: 35359000
[TBL] [Abstract][Full Text] [Related]
26. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
[TBL] [Abstract][Full Text] [Related]
27. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
28. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
29. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.
Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K
Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Ohno S; Shoji A; Hatake K; Oya N; Igarashi A
J Med Econ; 2020 Oct; 23(10):1130-1141. PubMed ID: 32620061
[TBL] [Abstract][Full Text] [Related]
32. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Haukaas FS; Ohna A; Krivasi T
Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
[TBL] [Abstract][Full Text] [Related]
34. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
35. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.
Hong X; Song Y; Shi Y; Zhang Q; Guo W; Wu G; Li J; Feng J; Kinkolykh A; Knapp A; Lin T
Chin Med J (Engl); 2021 Sep; 135(4):433-440. PubMed ID: 35194005
[TBL] [Abstract][Full Text] [Related]
37. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).
Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW
Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122
[TBL] [Abstract][Full Text] [Related]
38. Consolidation with
Miura K; Tsujimura H; Masaki Y; Iino M; Takizawa J; Maeda Y; Yamamoto K; Tamura S; Yoshida A; Yagi H; Yoshida I; Kitazume K; Masunari T; Choi I; Kakinoki Y; Suzuki R; Yoshino T; Nakamura S; Hatta Y; Yoshida T; Kanno M
Hematol Oncol; 2021 Feb; 39(1):51-59. PubMed ID: 32978820
[TBL] [Abstract][Full Text] [Related]
39. Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
Baek GT; Mathis NJ; Perissinotti AJ; Marini BL; Brown A; Phillips TJ; Wilcox RA; Nachar VR
Leuk Lymphoma; 2021 Dec; 62(13):3138-3146. PubMed ID: 34263702
[TBL] [Abstract][Full Text] [Related]
40. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
